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Abstract
Priming of T cells is a key event in vaccination, since it bears a decisive influence on the type and magnitude of the immune
response. T-cell priming after mucosal immunization via the nasal route was studied by investigating the distribution of
antigen-loaded antigen presenting cells (APCs) and primed antigen-specific T cells. Nasal immunization studies were
conducted using the model protein antigen ovalbumin (OVA) plus CpG oligodeoxynucleotide adjuvant. Trafficking of
antigen-specific primed T cells was analyzed in vivo after adoptive transfer of OVA-specific transgenic T cells in the presence
or absence of fingolimod, a drug that causes lymphocytes sequestration within lymph nodes. Antigen-loaded APCs were
observed in mediastinal lymph nodes, draining the respiratory tract, but not in distal lymph nodes. Antigen-specific
proliferating T cells were first observed within draining lymph nodes, and later in distal iliac and mesenteric lymph nodes
and in the spleen. The presence at distal sites was due to migration of locally primed T cells as shown by fingolimod
treatment that caused a drastic reduction of proliferated T cells in non-draining lymph nodes and an accumulation of
extensively divided T cells within draining lymph nodes. Homing of nasally primed T cells in distal iliac lymph nodes was
CD62L-dependent, while entry into mesenteric lymph nodes depended on both CD62L and a4b7, as shown by in vivo
antibody-mediated inhibition of T-cell trafficking. These data, elucidating the trafficking of antigen-specific primed T cells to
non-draining peripheral and mucosa-associated lymph nodes following nasal immunization, provide relevant insights for
the design of vaccination strategies based on mucosal priming.
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Introduction
Mucosal T-cell priming is a critical early event that deeply
influences the type and magnitude of the immune response to local
vaccination. Mucosal inductive sites are constituted by organized
mucosa-associated lymphoid tissues (MALT) as well as local
mucosa-draining lymph nodes, where antigens (Ag) are taken up,
and B- and T-cell responses are induced [1]. The pattern of signals
received during the initial interactions between naı ¨ve CD4
+ T cells
and antigen presenting cells (APCs) determines T-helper activation
and differentiation in cells that are able to interact with cognate B
cells, regulating multiple stages of their immune function [2]. T-
cell priming indeed influences both B- and T-cell memory
generation, thus determining the success of a vaccination strategy
[3,4]. Recent studies have shown that the frequency of Ag-specific
primed CD4
+ T cells can predict the intensity of the secondary
humoral responses [5].
Crucial events in T-cell priming following mucosal vaccination,
including mechanisms of local Ag-uptake, APCs recruitment and
mobilization, as well as redistribution of primed T cells within
lymphoid compartments, need to be carefully elucidated to inform
the rational design of vaccination strategies. Dendritic cells (DCs)
play a major role in the immune surveillance of the mucosal
surfaces and in the initiation of immune responses. Upon
encounter with foreign antigens, DCs migrate from mucosa to
the nearest inductive site where they act as APCs [6]. Primary T-
cell response results in expansion of naı ¨ve Ag-specific T cells, with
generation of a pool of memory Ag-specific T lymphocytes [7].
The study of mucosal immune responses has been mainly focused
on the characterization of effector humoral responses [8–10], and
only recently mucosal T-cell priming is beginning to be elucidated
[11–14].
We have previously shown that after mucosal priming, Ag-
specific proliferated T cells are present also in distal non-draining
lymphoid compartments [15,16]. This can be due to a
dissemination of Ag-loaded DCs towards non-draining lymph
nodes and subsequent proliferation of resident T cells, or to a
redistribution of T cells primed in the lymphoid compartment
draining the immunization site.
In the present work we investigated the distribution of Ag-
loaded APCs, the subsequent CD4
+ and CD8
+ T-cell priming and
trafficking towards distal lymphoid sites after nasal immunization
with a model vaccine formulation constituted by ovalbumin
(OVA) plus CpG oligodeoxynuclotide (ODN) 1826 as adjuvant.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19346By using fluorescent OVA, we analyzed the distribution of Ag-
loaded APCs at different time points within draining and distal
lymph nodes and spleen. The trafficking of primed CD4
+ and
CD8
+ T cells was studied in mice adoptively transferred with TCR
transgenic T cells [17]. In vivo treatment with fingolimod
(FTY720), a drug that causes sequestration of T cells in lymph
nodes [18], was used to further characterize T-cell redistribution
to Ag-free lymph nodes. The role of migration molecules, such as
CD62L and a4b7, in homing of T cells primed by nasal
immunization to different lymphoid compartments was also
dissected using in vivo antibody blocking assays.
Results
1. Ag-bearing APCs localization after nasal immunization
We have previously observed that after nasal immunization,
primed T cells are present not only in draining lymph nodes but
also in distal lymphoid organs [15,16]. This can be due to a
dissemination of Ag-bearing DCs that leads to a local proliferation
of resident naı ¨ve T cells or a redistribution of primed T cells from
the lymphoid compartment draining the immunization site. To
study the fate of Ag-bearing APCs after mucosal administration,
OVA-Alexa fluor 647 conjugate was inoculated with the mucosal
adjuvant CpG ODN by the nasal route, and the presence of Ag-
loaded DCs and B cells was studied at different time points, in
both draining and distal lymph nodes and spleen. Following nasal
administration, Ag-loaded DCs (CD11c
+ MHC class II
+) and B
cells were observed mainly in mediastinal lymph nodes (Fig. 1),
with about 9% of OVA
+ DCs after 12 h, and 21% after 24 h (Fig.
1 A). OVA
+ B cells were also observed in mediastinal lymph nodes
24 h after immunization with about 10% of positive cells (Fig. 1 B).
Ag-loaded DCs and B cells declined 72 h after Ag administration
(Fig. 1). In distal lymphoid organs, OVA
+ DCs and B cells were
not detected at any time point (Fig. 1). These data indicate that
following nasal immunization Ag-loaded APCs are localized in
mediastinal lymph nodes that drain the respiratory tract, and do
not disseminate towards distal lymphoid sites.
2. Ag-specific T-cell proliferation and dissemination into
distal lymphoid organs
The lack of migration of Ag-bearing APCs towards distal
lymphoid organs following nasal immunization suggests that T
cells, primed within the mucosal inductive site, disseminate
towards distal lymph nodes. To demonstrate this, OVA-specific
transgenic (TgN) CD4
+ and CD8
+ T cells, labeled with CFSE,
were adoptively transferred into recipient mice that were
immunized with the model formulation OVA and CpG ODN
by the nasal route. Experiments were performed in the presence or
absence of FTY720, an analog of sphingosine 1-phosphate that
inhibits T lymphocyte egress from lymph nodes [18]. Since
FTY720 can affect also DCs migration [19,20], we started the
drug administration 18 hours after nasal immunization, in order
to allow respiratory DCs to migrate from airway to draining lymph
nodes and initiate Ag-presentation to resident T cells. The OVA-
specific clonal expansion was assessed in draining and distal lymph
nodes 5 days after nasal immunization, since we previously
demonstrated the presence of proliferated T cells within non
draining sites at this time point [15,16]. Mice nasally immunized
with OVA and CpG ODN in the absence of FTY720 showed an
Ag-specific clonal expansion of both CD4
+ and CD8
+ TgN cells in
cervical and mediastinal lymph nodes that act as draining lymph
nodes following intranasal immunization [21], and also in distal
iliac and mesenteric lymph nodes, and in the spleen (Fig. 2 A and
B). While a continuous division profile of T cells was observed in
draining lymph nodes with about 6 division peaks, early cell
generations were absent in non-draining lymph nodes (Fig. 2 A
and B). The treatment with FTY720 determined an accumulation
of more extensively divided T cells in draining cervical and
mediastinal lymph nodes with about 92% of proliferating
lymphocytes respect to 69% of untreated mice (Fig. 2 A). On
the contrary, in distal lymph nodes the presence of proliferating T
cells was drastically reduced by FTY720 treatment with about
40% and 19% of dividing cells in iliac and mesenteric lymph nodes
respectively, compared to about 60% observed in untreated mice
(Fig. 2 A). The same effect of FTY720 treatment was observed for
CD8
+ TgN T cells, both in draining and distal lymph nodes (Fig. 2
B). Furthermore, the higher percentages of proliferating T cells
observed in cervical and mediastinal lymph nodes of FTY720-
treated versus untreated mice, corresponded to a higher absolute
number of TgN CD4
+ and CD8
+ T cells present in the draining
lymph nodes, thus confirming the sequestration of lymphocytes
Figure 1. Time-course analysis of antigen-loaded APCs local-
ization. C57BL/6 mice were immunized by the nasal route with OVA-
Alexa fluor 647 conjugate (25 mg/mouse) and CpG ODN (20 mg/mouse).
At different time points (0, 12, 24 and 72 h), DCs and B cells were
isolated from draining (mediastinal [MedLN]) and distal (iliac [ILN],
mesenteric [MLN]) lymph nodes and spleen (SPL). The percentages of
DCs (A) and B cells (B) positive for fluorescent OVA were analysed by
flow cytometry. Shown is the percentage of OVA-Alexa fluor 647
positive cells among total live CD11c
+ MHC class II
+ cells purified using
anti CD11c-conjugated magnetic beads (A) or B220
+ cells (B).
doi:10.1371/journal.pone.0019346.g001
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between the amount of CD4
+ or CD8
+ TgN T cells measured in
FTY720-treated versus untreated mice was .1 in draining sites and
,1 in distal lymphoid organs, since the clonal expanded T cells
could not disseminate due to the fingolimod effect. Also in the
spleen the number of TgN T cells was reduced by FTY720
treatment (Fig. 2 C), even if no significant difference in the
percentage of proliferating CD4
+ and CD8
+ T cells was observed
(Fig. 2 A and B) .
Taken together these data demonstrate that after nasal
immunization, antigen-specific CD4
+ and CD8
+ T cells are
primed in the regional mucosa-draining lymph nodes and then
became able to leave the priming compartment and traffic towards
distal non-draining lymph nodes and spleen.
3. Migration molecules involved in dissemination of
nasally primed T cells towards distal lymphoid
compartments
The dissemination towards non-draining lymphoid sites of T
cells primed by nasal route was further characterized by
identifying the molecules involved in distal lymph nodes entry.
Naı ¨ve and central memory T cells express CD62L, a molecule that
regulates lymphocyte entry into peripheral lymph nodes by
mediating the leukocyte rolling on blood vessel endothelium
[22,23]. After nasal immunization with OVA and CpG ODN,
about 40% of CD4
+ and 50% of CD8
+ T cells were CD62L-
positive in cervical lymph nodes (Fig. 3 A). To establish the role of
CD62L in homing of primed T lymphocytes into distal lymphoid
organs following nasal immunization, groups of mice immunized
with OVA and CpG ODN were treated with anti-CD62L or
isotype control antibodies beginning 6 h after immunization, and
continuing every 24 h until day 5. The treatment with anti-
CD62L dramatically reduced the presence of CD4
+ and CD8
+
TgN T cells within distal iliac lymph nodes, while did not prevent
the T-cell entry into mesenteric lymph nodes or spleens (Fig. 3 B
and C). The absolute number of CD4
+ and CD8
+ TgN T cells
detected in draining lymph nodes of mice treated with anti-
CD62L antibodies was lower than isotype control-treated mice
(Fig. 3 D), thus demonstrating that the early treatment with anti-
CD62L antibody blocks the recruitment of naı ¨ve Ag-specific T
cells within the draining lymph nodes. Also in distal lymph nodes
the number of T cells in mice treated with anti-CD62L antibodies
was lower than control mice (Fig. 3 D). T cells primed in cervical
and mediastinal lymph nodes were therefore allowed to leave the
draining site, but not to re-enter in distal iliac lymph nodes, due to
the blocking of L-selectin. On the contrary, only a slight reduction
in the amount of primed T cells was observed in mesenteric lymph
nodes following anti-CD62L treatment (Fig. 3 D), where primed T
cells were still allowed to enter (Fig. 3 B and C); this can be
explained by the role played by a4b7 molecule that regulates the
lymphocyte entry in mesenteric lymph nodes [24,25]. This
integrin was indeed expressed by more than 25% of TgN cells
collected from mesenteric lymph nodes in control mice (data not
shown). To further characterise the role of a4b7 in homing of
primed T lymphocytes into distal lymphoid organs, groups of mice
nasally immunized with OVA and CpG ODN were daily treated
with anti-a4b7 or with anti-a4b7 plus anti-CD62L. The treatment
with anti-a4b7 antibody was able to reduce, but not to completely
block, the entry of primed CD4
+ and CD8
+ TgN T cells within
mesenteric lymph nodes (Fig. 3 B and C). The total blockage of
primed T-cell entry within mesenteric lymph nodes was obtained
by administering anti-a4b7 and anti-CD62L antibodies together
(Fig. 3 B and C). In the spleen we did not observe a decrease of
primed T cells following anti-CD62L antibody treatment, while a
significant reduction of migrated T cells was reported after anti-
a4b7 administration (Fig. 3 D). Collectively, these results indicate
that CD62L plays a critical role in homing of nasally primed T
lymphocytes in iliac lymph nodes while the entrance of primed T
cells within mesenteric lymph nodes is dependent on both CD62L
and a4b7.
Discussion
In this work we show that T cells - and not antigen-loaded APCs
- primed by the nasal route with OVA and CpG ODN migrate to
distal lymph nodes and to the spleen, and that the entry of nasally
primed T cells into iliac lymph nodes is strictly CD62L-dependent,
while homing to mesenteric lymph nodes is regulated by both
CD62L and a4b7.
We have previously observed that divided T cells, primed by
nasal immunization, are detectable in distal lymphoid organs,
such as iliac and mesenteric lymph nodes and in the spleen
[15,16] and we hypothesized that this could be due to the
dissemination of Ag-bearing APCs into distal lymphoid sites, or to
the redistribution of T cells primed in the draining lymph nodes.
It is commonly accepted, mostly from Langerhans cells studies
[26], that Ag-loaded APCs terminally migrate to draining lymph
nodes where they present the antigen to cognate T and B cells
residing within the lymphoid organ [27]. However, it has been
recently shown that selected adjuvant molecules are able to alter
the migratory properties of DCs leaving the vaccination site,
allowing a fraction of these mobilized DCs to evade sequestration
within draining lymph nodes and localize in other secondary
lymphoid organs [28]. Here, we clearly demonstrated that upon
nasal immunization with OVA and CpG ODN, OVA-bearing
DCs and B cells were observed only in draining lymph nodes, and
not in any distal lymph nodes or in the spleen. This is in line with
what observed after nasal instillation of the fluorescent dye CFSE,
that showed an accumulation of fluorescent DCs predominantly
within draining lymph nodes but not in other lymphoid organs
[29,30]. It has also been shown that CpG adjuvant is unable to
alter the migratory properties of DCs after injection in the
footpad [31].
The redistribution of primed CD4
+ and CD8
+ T cells in distal
lymphoid sites was demonstrated by treating mice with FTY720.
Mice treated with FTY720 showed a higher accumulation of more
extensively divided T cells within draining (cervical and medias-
tinal) lymph nodes, while in distal lymph nodes the percentage of
divided TgN cells was largely reduced. The sequestration of
lymphocytes within the priming sites was also confirmed by the
higher count of TgN T cells retained in draining lymph nodes of
FTY720-treated mice compared to control. These data show that
following nasal immunization with OVA and CpG, priming of T
lymphocytes occurs in the draining lymph nodes and then
activated cells disseminate towards non-draining lymphoid
compartments. This is in line with what was recently reported
following systemic [32], oral [33] and sublingual [34] immuniza-
tion. The results reported in this study obtained using CpG ODN
as adjuvant, were comparable with what observed using different
adjuvants, (i.e. cholera toxin B subunit and alpha-galactosylcer-
amide; data not shown), suggesting that our observations do not
depend on the specific adjuvant employed. These data, showing
the expansion and dissemination of antigen-specific primed T cells
following intranasal vaccination, demonstrate that the mucosal
route of immunization via the respiratory tract can be very
efficient in vaccine priming. These findings provide the conceptual
basis for the development of combined mucosal/parenteral prime-
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CD4
+ and CD8
+ T cells, isolated from OT-II and OT-I mice, were labelled with CFSE and adoptively transferred into recipient C57BL/6 Ly5.1 mice.
Twenty-four hours later, recipient mice were immunized with OVA (25 mg/mouse) and CpG ODN (20 mg/mouse) by the nasal route. FTY720 was
administered i.p. 18 h after immunization and every 24 h until harvest 5 days after immunization. A–B. CD4
+ (A) and CD8
+ (B) TgN T- cell proliferation
assessed in cervical (CLN), mediastinal (MedLN), iliac (ILN), and mesenteric (MLN) lymph nodes, and spleen (SPL), by CFSE dilution. Histograms are
gated on CD4
+ CD45.2
+ (A) or CD8
+ CD45.2
+ (B) population, with light scatter properties of lymphocytes. Results are representative of three
Primed T-Cell Distribution upon Nasal Vaccination
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than either route alone [35,36].
Migration of lymphoid cells throughout the body is regulated by
the expression of multiple adhesion molecules and chemokine
receptors that interact with corresponding ligands on endothelial
and stromal cells. T-cell access to peripheral lymph nodes is
mediated by the expression of molecules such as CD62L that
controls rolling events on blood vessel endothelium by interacting
with peripheral lymph node addressin (PNAd) [22,23]. CD62L is
well expressed on naı ¨ve and central memory T cells, while is down
regulated on effector cells. Another molecule that plays an
important role in the recruitment of circulating lymphocytes to
the immune system of the gastrointestinal tract is the integrin a4b7
[24,25] which binds to mucosal addressin cell adhesion molecule-1
(MAdCAM-1), a ligand preferentially expressed on high endothe-
lial venules of Peyer’s Patches, mesenteric lymph nodes and
intestinal lamina propria [37]. Here we provide evidence that after
nasal immunization with OVA and CpG ODN, about 40% of
CD4
+ and 50% of CD8
+ primed T lymphocytes present in
draining lymph nodes still expressed CD62L, thus suggesting that
these cells use this molecule to disseminate towards distal lymph
nodes. To demonstrate the role of CD62L and a4b7 in the
redistribution of nasally primed T cells in peripheral and mucosa-
associated lymph nodes, we treated mice with anti-CD62L or anti-
a4b7 antibodies. After blocking CD62L molecule, the migration of
activated T cells into iliac lymph nodes was markedly inhibited,
while the entry of cells into the spleen and mesenteric lymph nodes
was not prevented. The absolute number of TgN T cells in iliac
lymph nodes of mice treated with anti-CD62L antibodies was
lower compared to control mice, thus confirming the block of
entry. The anti-CD62L antibody treatment shows that primed T
cells in cervical and mediastinal lymph nodes are allowed to leave
the draining site, but not to re-enter in distal iliac lymph nodes,
demonstrating that the dissemination of primed T cells in the iliac
lymph nodes is mediated by the expression of CD62L. In the
spleen we did not observe a decrease of primed T cells following
antibody treatment, since CD62L is not involved into spleen
homing [38]. We also observed that CD62L plays a critical role in
the continuous recruitment of naı ¨ve OVA-specific T cells within
draining lymph nodes during the priming event, as shown by the
reduced counts of CD4
+ and CD8
+ TgN T cells and the different
profiles of dividing cells in antibody-treated compared to control
mice. As reported by Jenkins and colleagues [39], after parenteral
immunization about a half of Ag-specific T cells inside the
draining lymph nodes are late-arriving cells, and their progeny still
express CD62L consistent with a memory phenotype.
The entry of nasally primed T cells into mesenteric lymph nodes
was inhibited by neither anti-CD62L nor anti-a4b7 antibody
treatment alone, but only by administration of both antibodies,
demonstrating regulation by both CD62L and a4b7. Thus, here
we show that CD62L and a4b7 promote entry into mesenteric
lymph nodes of nasally primed T cells and not only of naı ¨ve T cells
as previously reported [40,41]. Interestingly, the treatment with
anti-a4b7 altered also the migration of primed T cells into the
spleen, as shown by the lower absolute number of TgN T cells,
especially cytotoxic lymphocytes, compared to control mice. It has
been shown that MAdCAM-1 is highly expressed on sinus lining
cells closest to the lymphoid white pulp of the spleen [42], and this
receptor-ligand interaction can be responsible for the observed
migration of proliferated T cells into the spleen.
These data, elucidating the dissemination of primed T cells to
distal lymphoid organs following nasal immunization, expand the
knowledge on functioning of the mucosal immune system and
have important implications for rational design of optimised
vaccination strategies and prime-boost schemes.
Methods
Ethics Statement
Mice were housed in the animal facilities at the University of
Siena (Decreto nu 146 2005-A) and treated according to national
guidelines (Decreto Legislativo 27/01/1992 nu 116, implementing
86/609/CEE Directive). All animal studies were approved by the
Ethics Committee ‘‘Comitato Etico Locale dell’Azienda Ospeda-
liera Universitaria Senese’’ (protocol number 22933).
Mice
Nine-weeks old female OT-I [43] and OT-II [44] TCR-
transgenic mice, C57BL/6 and C57BL/6-Ly5.1 mice were
purchased from Charles River (Lecco, Italy). Transgenic mice
were maintained under specific pathogen-free conditions.
Nasal immunization with fluorescent OVA and DCs
isolation
OVA uptake was tracked in vivo using Ovalbumin-Alexa fluor
647 conjugate (Invitrogen Molecular Probes, Eugene, OR, USA).
The fluorescent OVA (25 mg/mouse) was mixed with the mucosal
adjuvant CpG oligodeoxynuclotide (ODN) 1826 (Eurofins MWG
Operon, Ebersberg, Germany) (20 mg/mouse) and administered
by nasal route. C57BL/6 mice were lightly anaesthetized by
intraperitoneal injection of tiletamine and zolazepam hydrochlo-
ride (Zoletil 20, Laboratoires Virbac, France, 6 mg/kg) and
xylazine (Xilor 2%, Bio 98 Srl, Italy, 3 mg/kg), held in a vertical
position and then inoculated drop wise into the nostrils in a total
volume of 20 ml. Groups of four mice were sacrificed 0, 12, 24 and
72 h after nasal immunization. Mediastinal, iliac and mesenteric
lymph nodes and spleens were harvested and digested in Click’s
medium (Sigma-Aldrich) with 2 mg/ml of Collagenase D (Roche
Applied Science, Penzberg, Germany) for 30 min at 37uC. Organs
were mashed onto nylon screens (Sefar Italia, Torino, Italy) and
washed in phosphate buffered saline (PBS) with 0.5% of bovine
serum albumin (BSA, Sigma-Aldrich) and 2 mM EDTA (Mal-
linckrodt Baker, Philipsburg, NJ, USA). DCs were purified by
magnetic activating cell sorting (MACS) using CD11c-conjugated
microbeads (Miltenyi Biotec GmbH, Germany) according to
manufacturer’s instructions.
Adoptive transfer of transgenic T cells
Single-cell suspensions from the spleen and pooled lymph nodes
(cervical, brachial, axillary, mesenteric and iliac lymph nodes) of
OT-I and OT-II transgenic mice were enriched for CD8
+ and
CD4
+ T cells using the EasySep negative CD8
+ and CD4
+ T cell
enrichment kit, respectively (StemCell Technologies, Vancouver,
BC, Canada) according to the manufacturer’s protocol. CD8
+ and
CD4
+ T cells were stained with carboxy-fluorescein diacetate
succinimidyl ester (CFSE, 7.5 mM, Invitrogen, USA) [45], for
independent experiments performed with three mice per group. Reported values indicate the percentage of dividing OVA-specific TgN T cells.
C. Ratio between the absolute number of OVA-specific CD4
+ and CD8
+ TgN T cells detected in FTY720- treated versus untreated mice. Values of ratios
for each organ are reported.
doi:10.1371/journal.pone.0019346.g002
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6 of mixed CFSE-labelled
CD8
+ and CD4
+ T cells was injected into the tail vein of the
recipient C57BL/6-Ly5.1 mice.
FTY720 treatment and in vivo Ab-mediated blocking of
migration molecules
Twenty-four hours after adoptive transfer of CFSE-labelled
OT-I CD8
+ and OT-II CD4
+ T cells, recipient C57BL/6-Ly5.1
mice were immunized with 25 or 100 mg of OVA (Sigma-Aldrich)
and 20 mg of CpG ODN administered by nasal route as described
above. To prevent T-cell egress from lymph nodes, mice were
injected i.p. with 1 mg/Kg body weight of FTY720 (Merck
Chemicals, Nottingham, UK) in 100 ml of PBS 18 h after
immunization and then every 24 h until harvest. In other
experiments, purified anti-CD62L (MEL-14, Southern Biotech-
nology, USA), anti-a4b7 (DATK-32, eBioscience, USA) or rat
IgG2a isotype control (eBioscience) were administered i.v. at
100 mg/mouse 6 h after immunization and then every 24 h until
harvest. Five days after immunization, lymph nodes and spleens
were collected and analysed by flow cytometry.
Flow cytometric analysis
Single-cell suspensions from cervical, mediastinal, iliac and
mesenteric lymph nodes and spleens were obtained as previously
described [46]. Cells were incubated with Fc-blocking solution
[0.5 mg CD16/CD32 mAb (clone 93) (eBioscience), 5% mouse
serum, 5% rat serum, 0.2% sodium azide (all from Sigma-Aldrich)
in 100 ml of HBSS] for 30 min on ice. Cells were stained with
PerCP-conjugated anti-mouse CD4 (clone RM 4-5) or CD8 (clone
53-6.7) (BD Pharmingen), PE-conjugated anti-mouse CD45.2
(clone 104) and with APC-conjugated anti-mouse CD62L (Ly-22)
(clone MEL-14) (all from eBioscience) for 30 min on ice. Analysis
of T-cell clonal expansion was performed on single samples
collected from each animal. The absolute number of transgenic T
cells detected in each organ was determined by using CountBright
absolute counting beads (Invitrogen Molecular Probes, USA)
according to the manufacturer’s protocol.
DCs present in the CD11c-positive fraction after MACS were
labelled with FITC-conjugated I-A/I-E (clone M5/114.15.2), PE-
conjugated CD11c (clone N418) (all from eBioscience), and
propidium iodide (Sigma-Aldrich) for excluding dead cells. B cells
present in the CD11c-negative fraction were labelled with PerCP-
conjugated CD45R/B220 (clone RA3-6B2, BD Pharmingen).
Samples were analyzed by flow cytometry (FACScalibur, Becton
Dickinson, San Diego, CA). Data analysis was performed by using
Flow Jo software (Treestar, Ashland, OR, USA).
Statistical analysis
Statistical significance was assessed by Student’s t test. A value of
P#0.05 was considered significant.
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